Longeveron Gestione

Gestione criteri di controllo 0/4

Longeveron Il CEO è Mohamed Wa'el Hashad, nominato in Feb2023, e ha un mandato di 1.75 anni. la retribuzione annua totale è $ 1.66M, composta da 25.9% di stipendio e 74.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.88% delle azioni della società, per un valore di $ 525.91K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 2.4 anni.

Informazioni chiave

Mohamed Wa'el Hashad

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO	25.9%
Mandato del CEO	1.8yrs
Proprietà del CEO	1.9%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	2.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mohamed Wa'el Hashad rispetto agli utili di Longeveron?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$2m	US$431k	-US$22m

Compensazione vs Mercato: La retribuzione totale di Mohamed Wa'el ($USD 1.66M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Mohamed Wa'el con le performance aziendali.

AMMINISTRATORE DELEGATO

Mohamed Wa'el Hashad (62 yo)

1.8yrs

Mandato

US$1,662,854

Compensazione

Mr. Mohamed Wa'el Ahmed Hashad, M.B.A. has been Chief Executive Officer at Longeveron Inc. since February 2023 and also has been its Director since June 09, 2023. Mr. Hashad has been Independent Director a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joshua Hare	Co-Founder	10.8yrs	US$87.13k	8.02% $ 2.2m
Mohamed Wa'el Hashad	CEO & Director	1.8yrs	US$1.66m	1.88% $ 525.9k
Lisa Locklear	CFO & Treasurer	1.3yrs	US$604.67k	1.07% $ 299.2k
Paul Lehr	International Executive Director	no data	US$554.06k	1.08% $ 301.6k
Dan Gincel	Senior Vice President of Strategic Collaborations & Scientific Affairs	3.5yrs	Nessun dato	Nessun dato
Nataliya Agafonova	Chief Medical Officer	1.3yrs	Nessun dato	1.06% $ 298.3k
Lisa McClain-Moss	Vice President of Manufacturing	no data	Nessun dato	Nessun dato
Brian Rash	VP of Research & Discovery	no data	Nessun dato	Nessun dato
Elly Ryu	VP & Corporate Controller	less than a year	Nessun dato	Nessun dato
Michael Mannarino	VP & Corporate Controller	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di LGVN non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joshua Hare	Co-Founder	10.8yrs	US$87.13k	8.02% $ 2.2m
Mohamed Wa'el Hashad	CEO & Director	1.4yrs	US$1.66m	1.88% $ 525.9k
Roger Hajjar	Independent Director	less than a year	Nessun dato	Nessun dato
Richard Kender	Independent Director	less than a year	Nessun dato	Nessun dato
Joe G. Garcia	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Khoso Baluch	Independent Director	1.4yrs	US$47.78k	0.10% $ 28.1k
Jeremy Walston	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Elena Volpi	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Hidenori Arai	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Neil Hare	Director	9.2yrs	US$52.13k	2.06% $ 576.9k
Rock Soffer	Director	4.7yrs	US$55.63k	1.41% $ 394.1k
Ursula Ungaro	Independent Director	3.4yrs	US$62.63k	0.0034% $ 945.0

2.4yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LGVN non è considerato esperto (durata media del mandato 2.4 anni), il che suggerisce un nuovo consiglio.

Longeveron Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Recent updates

Consensus EPS estimates fall by 19%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024

Longeveron Inc. to Report Q3, 2024 Results on Nov 12, 2024

Longeveron Inc. Presents Lomecel-B™? Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron Inc. Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)

Consensus estimates of losses per share improve by 12%

Price target decreased by 31% to US$8.32

Consensus revenue estimates fall by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Consensus EPS estimates upgraded to US$3.42 loss

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million.

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Price target decreased by 12% to US$12.30

Consensus EPS estimates upgraded to US$3.91 loss

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind